Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland
The transition to targeted therapies has improved outcomes for high-risk CLL patients. Nevertheless, outcomes for high-risk CLL patients remain inferior to those reported in clinical trials, underscoring the need for real-world evidence and improved therapies.
Authors
- Liisa Ukkola‐Vuoti (ORCID: https://orcid.org/0000-0002-0770-361X)
- Emma‐Leena Alarmo (ORCID: https://orcid.org/0009-0008-7626-8368)
- Vesa Lindström (ORCID: https://orcid.org/0000-0001-5724-9120)
- Oscar E. Brück (ORCID: https://orcid.org/0000-0002-7842-9419)
- Tuija Tapaninen (ORCID: https://orcid.org/0000-0003-4562-9606)
- Olivia Hölsä (ORCID: https://orcid.org/0009-0007-8260-3356)
- Kimmo Porkka (ORCID: https://orcid.org/0000-0003-4112-5902)
Institutions
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- AstraZeneca (Finland) (FI)
- Cancer Society of Finland (FI)
- Hospital District of Helsinki and Uusimaa (FI)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1016/j.clml.2025.12.002
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00